Astrocytic JWA Expression is Essential to Dopaminergic Neuron Survival in the Pathogenesis of Parkinson's Disease

CNS Neuroscience and Therapeutics

Volumn 20, Issue 8, 2014, Pages 754-762

  Miao, Shu Han ^a   Sun, Hong Bin ^a   Ye, Yang ^a,b   Yang, Jing Jing ^a   Shi, Yao Wei ^a   Lu, Ming ^a   Hu, Gang ^a   Zhou, Jian Wei ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b JIANGSU UNIVERSITY   (China)

Author keywords

Dopamine; JWA; NF B; Parkinson's disease; Reactive oxygen species

Indexed keywords

GLIAL FIBRILLARY ACIDIC PROTEIN; GLUTATHIONE; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; REACTIVE OXYGEN METABOLITE; 3,4 DIHYDROXYPHENYLACETIC ACID; ARL6IP5 PROTEIN, MOUSE; CARRIER PROTEIN; DOPAMINE; HOMOVANILLIC ACID; I KAPPA B KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CELL SURVIVAL; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; GENE; GENE INACTIVATION; GLIOMA CELL; IMMUNOFLUORESCENCE TEST; IN VITRO STUDY; IN VIVO STUDY; JWA GENE; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA; ANIMAL; CELL LINE; DISEASE MODEL; DRUG EFFECTS; GENETIC TRANSFECTION; GENETICS; INTOXICATION; METABOLISM; NERVE CELL; PATHOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE;

3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; ASTROCYTES; CARRIER PROTEINS; CELL LINE; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DOPAMINE; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUTATHIONE; HOMOVANILLIC ACID; I-KAPPA B KINASE; MICE; MICE, TRANSGENIC; MPTP POISONING; NEURONS; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA; TRANSFECTION;

EID: 84904677833     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.12249     Document Type: Article

References (55)

1. Teismann P, Tieu K, Choi DK, et al. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc Natl Acad Sci USA 2003;100:5473-5478.
2. Moore DJ, West AB, Dawson VL, Dawson TM. Molecular pathophysiology of Parkinson's disease. Annu Rev Neurosci 2005;28:57-87.
3. Dauer W, Przedborski S. Parkinson's disease: Mechanisms and models. Neuron 2003;39:889-909.
4. Jackson-Lewis V, Blesa J, Przedborski S. Animal models of Parkinson's disease. Parkinsonism Relat Disord 2012;18(Suppl 1):S183-S185.
5. Dawson TM, Dawson VL. Molecular pathways of neurodegeneration in Parkinson's disease. Science 2003;302:819-822.
6. Kincses ZT, Vecsei L. Pharmacological therapy in Parkinson's disease: Focus on neuroprotection. CNS Neurosci Ther 2011;17:345-367.
7. Yoo MS, Chun HS, Son JJ, et al. Oxidative stress regulated genes in nigral dopaminergic neuronal cells: Correlation with the known pathology in Parkinson's disease. Brain Res Mol Brain Res 2003;110:76-84.
8. Chan P, DeLanney LE, Irwin I, Langston JW, Di Monte D. Rapid ATP loss caused by 1- methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine in mouse brain. J Neurochem 1991;57:348-351.
9. Nicotra A, Parvez S. Apoptotic molecules and MPTP-induced cell death. Neurotoxicol Teratol 2002;24:599-605.
10. Xu H, Jiang H, Wang J, Xie J. Rg1 protects the MPP+-treated MES23.5 cells via attenuating DMT1 up-regulation and cellular iron uptake. Neuropharmacology 2010;58:488-494.
11. Hayden MS, West AP, Ghosh S. NF-kappaB and the immune response. Oncogene 2006;25:6758-6780.
12. Tilstra JS, Robinson AR, Wang J, et al. NF-kappaB inhibition delays DNA damage-induced senescence and aging in mice. J Clin Invest 2012;122:2601-2612.
13. Sidoryk-Wegrzynowicz M, Wegrzynowicz M, Lee E, Bowman AB, Aschner M. Role of astrocytes in brain function and disease. Toxicol Pathol 2011;39:115-123.
14. Pekny M, Nilsson M. Astrocyte activation and reactive gliosis. Glia 2005;50:427-434.
15. Maragakis NJ, Rothstein JD. Glutamate transporters in neurologic disease. Arch Neurol 2001;58:365-370.
16. Walz W. Role of astrocytes in the clearance of excess extracellular potassium. Neurochem Int 2000;36:291-300.
17. Belanger M, Allaman I, Magistretti PJ. Brain energy metabolism: Focus on astrocyte-neuron metabolic cooperation. Cell Metab 2011;14:724-738.
18. Rappold PM, Tieu K. Astrocytes and therapeutics for Parkinson's disease. Neurotherapeutics 2010;7:413-423.
19. Lu M, Fan Y, Tang M, Qian X, Ding J, Hu G. Potentiation of D-serine involves degeneration of dopaminergic neurons in MPTP/p mouse model of Parkinson's disease. CNS Neurosci Ther 2011;17:796-798.
20. Chen H, Bai J, Ye J, et al. JWA as a functional molecule to regulate cancer cells migration via MAPK cascades and F-actin cytoskeleton. Cell Signal 2007;19:1315-1327.
21. Huang S, Shen Q, Mao WG, et al. JWA, a novel signaling molecule, involved in all-trans retinoic acid induced differentiation of HL-60 cells. J Biomed Sci 2006;13:357-371.
22. Huang S, Shen Q, Mao WG, et al. JWA, a novel signaling molecule, involved in the induction of differentiation of human myeloid leukemia cells. Biochem Biophys Res Commun 2006;341:440-450.
23. Wang S, Gong Z, Chen R, et al. JWA regulates XRCC1 and functions as a novel base excision repair protein in oxidative-stress-induced DNA single-strand breaks. Nucleic Acids Res 2009;37:1936-1950.
24. Chen R, Qiu W, Liu Z, et al. Identification of JWA as a novel functional gene responsive to environmental oxidative stress induced by benzo[a]pyrene and hydrogen peroxide. Free Radic Biol Med 2007;42:1704-1714.
25. Gong Z, Shi Y, Zhu Z, et al. JWA deficiency suppresses dimethylbenz[a]anthracene-phorbol ester induced skin papillomas via inactivation of MAPK pathway in mice. PLoS One 2012;7:e34154.
26. Shao W, Zhang SZ, Tang M, et al. Suppression of neuroinflammation by astrocytic dopamine D2 receptors via alphaB-crystallin. Nature 2013;494:90-94.
27. Lu M, Zhao FF, Tang JJ, et al. The neuroprotection of hydrogen sulfide against MPTP-induced dopaminergic neuron degeneration involves uncoupling protein 2 rather than ATP-sensitive potassium channels. Antioxid Redox Signal 2012;17:849-859.
28. Xie LL, Sun XL, Fan Y, Kong H, Ding JH, Hu G. Aquaporin 4 knockout resists negative regulation of neural cell proliferation by cocaine in mouse hippocampus. Int J Neuropsychopharmacol 2009;12:843-850.
29. Kilic E, ElAli A, Kilic U, et al. Role of Nogo-A in neuronal survival in the reperfused ischemic brain. J Cereb Blood Flow Metab 2010;30:969-984.
30. Yang W, Wu Q, Yuan C, et al. Aquaporin-4 mediates astrocyte response to beta-amyloid. Mol Cell Neurosci 2012;49:406-414.
31. Shen L, Xu W, Li A, Ye J, Zhou J. JWA enhances As(2)O(3)-induced tubulin polymerization and apoptosis via p38 in HeLa and MCF-7 cells. Apoptosis 2011;16:1177-1193.
32. Wang S, Wu X, Zhang J, et al. CHIP functions as a novel suppressor of tumour angiogenesis with prognostic significance in human gastric cancer. Gut 2013;62:496-508.
33. Lee HJ, Kim SH, Kim KW, et al. Antiapoptotic role of NF-kappaB in the auto-oxidized dopamine-induced apoptosis of PC12 cells. J Neurochem 2001;76:602-609.
34. Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry 1998;64:314-319.
35. Bosco DA, Fowler DM, Zhang Q, et al. Elevated levels of oxidized cholesterol metabolites in Lewy body disease brains accelerate alpha-synuclein fibrilization. Nat Chem Biol 2006;2:249-253.
36. Nakabeppu Y, Tsuchimoto D, Yamaguchi H, Sakumi K. Oxidative damage in nucleic acids and Parkinson's disease. J Neurosci Res 2007;85:919-934.
37. Zeevalk GD, Razmpour R, Bernard LP. Glutathione and Parkinson's disease: Is this the elephant in the room? Biomed Pharmacother 2008;62:236-249.
38. Chen R, Li A, Zhu T, et al. JWA - A novel environmental-responsive gene, involved in estrogen receptor-associated signal pathway in MCF-7 and MDA-MB-231 breast carcinoma cells. J Toxicol Environ Health A 2005;68:445-456.
39. Lotharius J, Brundin P. Impaired dopamine storage resulting from alpha-synuclein mutations may contribute to the pathogenesis of Parkinson's disease. Hum Mol Genet 2002;11:2395-2407.
40. Tashiro Y, Sugimoto T, Hattori T, et al. Tyrosine hydroxylase-like immunoreactive neurons in the striatum of the rat. Neurosci Lett 1989;97:6-10.
41. Betarbet R, Turner R, Chockkan V, et al. Dopaminergic neurons intrinsic to the primate striatum. J Neurosci 1997;17:6761-6768.
42. Meredith GE, Farrell T, Kellaghan P, Tan Y, Zahm DS, Totterdell S. Immunocytochemical characterization of catecholaminergic neurons in the rat striatum following dopamine-depleting lesions. Eur J Neurosci 1999;11:3585-3596.
43. Mao L, Lau YS, Petroske E, Wang JQ. Profound astrogenesis in the striatum of adult mice following nigrostriatal dopaminergic lesion by repeated MPTP administration. Brain Res Dev Brain Res 2001;131:57-65.
44. Mazloom M, Smith Y. Synaptic microcircuitry of tyrosine hydroxylase-containing neurons and terminals in the striatum of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-treated monkeys. J Comp Neurol 2006;495:453-469.
45. Huot P, Levesque M, Parent A. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea. Brain 2007;130:222-232.
46. Marchetti B, Abbracchio MP. To be or not to be (inflamed)-is that the question in anti-inflammatory drug therapy of neurodegenerative disorders? Trends Pharmacol Sci 2005;26:517-525.
47. Droge W. Free radicals in the physiological control of cell function. Physiol Rev 2002;82:47-95.
48. Kim JC, Lee YH, Yu MK, et al. Anti-inflammatory mechanism of PPARgamma on LPS-induced pulp cells: Role of the ROS removal activity. Arch Oral Biol 2012;57:392-400.
49. Zhao H, Wang SL, Qian L, et al. Diammonium glycyrrhizinate attenuates Abeta(1-42) -induced neuroinflammation and regulates MAPK and NF-kappaB pathways in vitro and in vivo. CNS Neurosci Ther 2013;19:117-124.
50. Lenardo MJ, Baltimore D. NF-kappa B: A pleiotropic mediator of inducible and tissue-specific gene control. Cell 1989;58:227-229.
51. Pahl HL, Baeuerle PA. The ER-overload response: Activation of NF-kappa B. Trends Biochem Sci 1997;22:63-67.
52. Arenzana-Seisdedos F, Thompson J, Rodriguez MS, Bachelerie F, Thomas D, Hay RT. Inducible nuclear expression of newly synthesized I kappa B alpha negatively regulates DNA-binding and transcriptional activities of NF-kappa B. Mol Cell Biol 1995;15:2689-2696.
53. Arenzana-Seisdedos F, Turpin P, Rodriguez M, et al. Nuclear localization of I kappa B alpha promotes active transport of NF-kappa B from the nucleus to the cytoplasm. J Cell Sci 1997;110(Pt 3):369-378.
54. Kareus SA, Figueroa KP, Cannon-Albright LA, Pulst SM. Shared predispositions of parkinsonism and cancer: A population-based pedigree-linked study. Arch Neurol 2012;69:1572-1577.
55. Bai J, Zhang J, Wu J, et al. JWA regulates melanoma metastasis by integrin alphaVbeta3 signaling. Oncogene 2010;29:1227-1237.